BIOMAT Database Logo BIOMAT Database Logo

Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells. 2022

Najla Santos Pacheco de Campos, and Adriano de Oliveira Beserra, and Pedro Henrique Barbosa Pereira, and Alexandre Silva Chaves, and Fernando Luiz Affonso Fonseca, and Tiago da Silva Medina, and Tiago Goss Dos Santos, and Yufei Wang, and Wayne Anthony Marasco, and Eloah Rabello Suarez
Center for Natural and Human Sciences, Federal University of ABC, Santo Andre 09210-580, SP, Brazil.

The complete regression of clear cell renal cell carcinoma (ccRCC) obtained pre-clinically with anti-carbonic anhydrase IX (CAIX) G36 chimeric antigen receptor (CAR) T cells in doses equivalent to ≅108 CAR T cells/kg renewed the potential of this target to treat ccRCC and other tumors in hypoxia. The immune checkpoint blockade (ICB) brought durable clinical responses in advanced ccRCC and other tumors. Here, we tested CD8α/4-1BB compared to CD28-based anti-CAIX CAR peripheral blood mononuclear cells (PBMCs) releasing anti-programmed cell death ligand-1 (PD-L1) IgG4 for human ccRCC treatment in vitro and in an orthotopic NSG mice model in vivo. Using a ≅107 CAR PBMCs cells/kg dose, anti-CAIX CD28 CAR T cells releasing anti-PD-L1 IgG highly decrease both tumor volume and weight in vivo, avoiding the occurrence of metastasis. This antitumoral superiority of CD28-based CAR PBMCs cells compared to 4-1BB occurred under ICB via PD-L1. Furthermore, the T cell exhaustion status in peripheral CD4 T cells, additionally to CD8, was critical for CAR T cells efficiency. The lack of hepatotoxicity and nephrotoxicity upon the administration of a 107 CAR PMBCs cells/kg dose is the basis for carrying out clinical trials using anti-CAIX CD28 CAR PBMCs cells releasing anti-PD-L1 antibodies or anti-CAIX 4-1BB CAR T cells, offering exciting new prospects for the treatment of refractory ccRCC and hypoxic tumors.

UI MeSH Term Description Entries
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D002292 Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. Adenocarcinoma, Renal Cell,Carcinoma, Hypernephroid,Grawitz Tumor,Hypernephroma,Renal Carcinoma,Adenocarcinoma Of Kidney,Adenocarcinoma, Renal,Chromophil Renal Cell Carcinoma,Chromophobe Renal Cell Carcinoma,Clear Cell Renal Carcinoma,Clear Cell Renal Cell Carcinoma,Collecting Duct Carcinoma,Collecting Duct Carcinoma (Kidney),Collecting Duct Carcinoma of the Kidney,Nephroid Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Cancer,Renal Cell Carcinoma,Renal Cell Carcinoma, Papillary,Renal Collecting Duct Carcinoma,Sarcomatoid Renal Cell Carcinoma,Adenocarcinoma Of Kidneys,Adenocarcinomas, Renal Cell,Cancer, Renal Cell,Carcinoma, Collecting Duct,Carcinoma, Collecting Duct (Kidney),Carcinoma, Nephroid,Carcinoma, Renal,Carcinomas, Collecting Duct,Carcinomas, Collecting Duct (Kidney),Carcinomas, Renal Cell,Collecting Duct Carcinomas,Collecting Duct Carcinomas (Kidney),Hypernephroid Carcinoma,Hypernephroid Carcinomas,Hypernephromas,Kidney, Adenocarcinoma Of,Nephroid Carcinomas,Renal Adenocarcinoma,Renal Adenocarcinomas,Renal Carcinomas,Renal Cell Adenocarcinoma,Renal Cell Adenocarcinomas,Renal Cell Cancers,Renal Cell Carcinomas,Tumor, Grawitz
D000071231 Carbonic Anhydrase IX A carbonic anhydrase and transmembrane protein that consists of an N-terminal PROTEOGLYCAN-like domain, a catalytic region, a single-pass transmembrane domain, and a short intracellular tail. It functions as a dimer and is expressed primarily by cells of the GASTROINTESTINAL TRACT; BILE DUCT EPITHELIUM; and GALL BLADDER. It is expressed at high levels in many solid tumors, especially CLEAR CELL RENAL CARCINOMA, in response to CELL HYPOXIA. CAIX Protein,Carbonic Anhydrase 9
D000076962 Receptors, Chimeric Antigen Synthetic cellular receptors that reprogram T-LYMPHOCYTES to selectively bind antigens. Chimeric Antigen Receptor,Chimeric T-Cell Receptor,Artificial T-Cell Receptors,Chimeric Antigen Receptors,Chimeric Immunoreceptors,Chimeric T-Cell Receptors,Antigen Receptor, Chimeric,Antigen Receptors, Chimeric,Artificial T Cell Receptors,Chimeric T Cell Receptor,Chimeric T Cell Receptors,Immunoreceptors, Chimeric,Receptor, Chimeric Antigen,Receptor, Chimeric T-Cell,Receptors, Artificial T-Cell,Receptors, Chimeric T-Cell,T-Cell Receptor, Chimeric,T-Cell Receptors, Artificial,T-Cell Receptors, Chimeric
D000082082 Immune Checkpoint Inhibitors Drugs that block negative regulator IMMUNE CHECKPOINT proteins (e.g., PD-1 RECEPTOR and CTLA-4 ANTIGEN) thereby increasing suppressed immune activation in immunotherapies. CTLA-4 Inhibitor,CTLA-4 Inhibitors,Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor,Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitors,Immune Checkpoint Blockade,Immune Checkpoint Blockers,Immune Checkpoint Inhibition,Immune Checkpoint Inhibitor,PD-1 Inhibitor,PD-1 Inhibitors,PD-1-PD-L1 Blockade,PD-L1 Inhibitor,PD-L1 Inhibitors,Programmed Cell Death Protein 1 Inhibitor,Programmed Cell Death Protein 1 Inhibitors,Programmed Death-Ligand 1 Inhibitors,Blockade, PD-1-PD-L1,CTLA 4 Inhibitor,CTLA 4 Inhibitors,Checkpoint Blockade, Immune,Checkpoint Blockers, Immune,Checkpoint Inhibition, Immune,Checkpoint Inhibitor, Immune,Checkpoint Inhibitors, Immune,Cytotoxic T Lymphocyte Associated Protein 4 Inhibitor,Cytotoxic T Lymphocyte Associated Protein 4 Inhibitors,Inhibitor, PD-1,PD 1 Inhibitor,PD 1 Inhibitors,PD 1 PD L1 Blockade,PD L1 Inhibitor,PD L1 Inhibitors,Programmed Death Ligand 1 Inhibitors
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Najla Santos Pacheco de Campos, and Adriano de Oliveira Beserra, and Pedro Henrique Barbosa Pereira, and Alexandre Silva Chaves, and Fernando Luiz Affonso Fonseca, and Tiago da Silva Medina, and Tiago Goss Dos Santos, and Yufei Wang, and Wayne Anthony Marasco, and Eloah Rabello Suarez
Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
November 2023, Human gene therapy,
Najla Santos Pacheco de Campos, and Adriano de Oliveira Beserra, and Pedro Henrique Barbosa Pereira, and Alexandre Silva Chaves, and Fernando Luiz Affonso Fonseca, and Tiago da Silva Medina, and Tiago Goss Dos Santos, and Yufei Wang, and Wayne Anthony Marasco, and Eloah Rabello Suarez
Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer.
June 2020, Molecular therapy oncolytics,
Najla Santos Pacheco de Campos, and Adriano de Oliveira Beserra, and Pedro Henrique Barbosa Pereira, and Alexandre Silva Chaves, and Fernando Luiz Affonso Fonseca, and Tiago da Silva Medina, and Tiago Goss Dos Santos, and Yufei Wang, and Wayne Anthony Marasco, and Eloah Rabello Suarez
4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells.
January 2020, Frontiers in immunology,
Najla Santos Pacheco de Campos, and Adriano de Oliveira Beserra, and Pedro Henrique Barbosa Pereira, and Alexandre Silva Chaves, and Fernando Luiz Affonso Fonseca, and Tiago da Silva Medina, and Tiago Goss Dos Santos, and Yufei Wang, and Wayne Anthony Marasco, and Eloah Rabello Suarez
Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade.
April 2018, Nature communications,
Najla Santos Pacheco de Campos, and Adriano de Oliveira Beserra, and Pedro Henrique Barbosa Pereira, and Alexandre Silva Chaves, and Fernando Luiz Affonso Fonseca, and Tiago da Silva Medina, and Tiago Goss Dos Santos, and Yufei Wang, and Wayne Anthony Marasco, and Eloah Rabello Suarez
Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade.
July 2021, Journal for immunotherapy of cancer,
Najla Santos Pacheco de Campos, and Adriano de Oliveira Beserra, and Pedro Henrique Barbosa Pereira, and Alexandre Silva Chaves, and Fernando Luiz Affonso Fonseca, and Tiago da Silva Medina, and Tiago Goss Dos Santos, and Yufei Wang, and Wayne Anthony Marasco, and Eloah Rabello Suarez
Chimeric Antigen Receptor-T Cells with 4-1BB Co-Stimulatory Domain Present a Superior Treatment Outcome than Those with CD28 Domain Based on Bioinformatics.
January 2018, Acta haematologica,
Najla Santos Pacheco de Campos, and Adriano de Oliveira Beserra, and Pedro Henrique Barbosa Pereira, and Alexandre Silva Chaves, and Fernando Luiz Affonso Fonseca, and Tiago da Silva Medina, and Tiago Goss Dos Santos, and Yufei Wang, and Wayne Anthony Marasco, and Eloah Rabello Suarez
Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition.
December 2022, International immunopharmacology,
Najla Santos Pacheco de Campos, and Adriano de Oliveira Beserra, and Pedro Henrique Barbosa Pereira, and Alexandre Silva Chaves, and Fernando Luiz Affonso Fonseca, and Tiago da Silva Medina, and Tiago Goss Dos Santos, and Yufei Wang, and Wayne Anthony Marasco, and Eloah Rabello Suarez
Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically.
July 2019, Cancer immunology research,
Najla Santos Pacheco de Campos, and Adriano de Oliveira Beserra, and Pedro Henrique Barbosa Pereira, and Alexandre Silva Chaves, and Fernando Luiz Affonso Fonseca, and Tiago da Silva Medina, and Tiago Goss Dos Santos, and Yufei Wang, and Wayne Anthony Marasco, and Eloah Rabello Suarez
Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth.
January 2020, Biomarker research,
Najla Santos Pacheco de Campos, and Adriano de Oliveira Beserra, and Pedro Henrique Barbosa Pereira, and Alexandre Silva Chaves, and Fernando Luiz Affonso Fonseca, and Tiago da Silva Medina, and Tiago Goss Dos Santos, and Yufei Wang, and Wayne Anthony Marasco, and Eloah Rabello Suarez
Anti-4-1BB×PD-L1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD-1 Blockade.
May 2024, Clinical cancer research : an official journal of the American Association for Cancer Research,
Copied contents to your clipboard!